The aim of this study was to evaluate the clinical utility of pneumococcal and legionella urinary antigen testing and its cost effectiveness within Western Health, a tertiary public hospital servicing the west of Melbourne. October 2017 with a diagnosis of community-acquired pneumonia were included. Medical records were reviewed to evaluate the proportion of cases where antibiotic treatment was de-escalated in the setting of a positive urinary antigen result. Observance of local guidelines for diagnostic testing and evaluation of cost-benefit analysis of urinary antigens were also assessed.
included. Medical records were reviewed to evaluate the proportion of cases where antibiotic treatment was de-escalated in the setting of a positive urinary antigen result. Observance of local guidelines for diagnostic testing and evaluation of cost-benefit analysis of urinary antigens were also assessed.
Results: Preliminary results demonstrate a low prevalence of positive urinary antigen in our study population. Positive urinary antigen tests resulted in de-escalation from empirical to targeted antibiotics in only a small proportion of cases.
Conclusion:
The diagnostic and clinical utility of pneumococcal and legionella urinary antigens is low in community-acquired pneumonia. Due to the low prevalence of positive urinary antigen results, routine testing in hospitalised patients is not cost-effective. Nagasaki University School of Medicine, Japan Background and Aims: The Diagnostic Procedure Combination (DPC), which is a huge inpatient database and links with a lump-sum payment system that has introduced by the Japanese government in 2002, has been actively used for evaluating pneumonia patients. According to the 2017 Japanese guidelines, it is weakly recommended to add low-dose corticosteroid to antibiotic therapy for severe pneumonia patients. However, the efficacy of corticosteroid add-on therapy for severe communityonset pneumonia patients remains unclear. We therefore evaluated the efficacy of corticosteroid add-on treatment for severe pneumonia using the DPC database.
Methods: Adult patients with severe community-onset pneumonia patients (more than 3 points in the A-DROP system) treated in hospital between January and December 2012 were identified in the DPC database. The background factors were adjusted using the inverse probability of treatment weighting (IPTW) method, and the patients that high-dose corticosteroids (methylprednisolone ≧500 mg/day) were administered were excluded. The patients were divided into two groups based on the presence or absence of low-dose corticosteroid treatment in addition to antibiotic therapy. The 30-day survival rate was evaluated using the Kaplan-Meier method.
Results: The average ages and male ratios of the corticosteroid addon (A) group (1,338 patients) and corticosteroid non-add-on (B) group (11,939 patients) were 81.6 and 83.4 years old, 67.2% and 61.0%, respectively. We found no significant differences of the 30-day survival rate between A and B group (weighted hazard ratio: 1.08; 95% confidence interval: 0.91-1.29; P = 0.38).
Conclusion: Low-dose corticosteroid add-on therapy in addition to antibiotic medication for severe community-onset pneumonia patients may not be related to an improvement of the prognosis. Results: During the study period, 1,021 patients were eligible for the study. 121 patients died during the initial hospitalization, 35 patients discharged against medical advice and refused outpatient follow up, and 3 patients transferred to another acute care facility. Of the 862 patients who survived to hospital discharge, 72 (8.4%) were rehospitalized within 30 days following discharge. Pneumonia-related causes accounted for 37.5% (27 patients) and pneumonia-unrelated causes accounted for 62.5% (45 patients) of the total reasons for 30 day readmission. In the multivariable analysis, pneumonia related hospital readmission was associated with para/hemiplegia, malignancy, pneumonia severity index (PSI) class ≥4 and clinical instability ≥1 at hospital discharge. Underlying comorbidities such as chronic lung disease, chronic kidney disease, hospitalization for ≥2 days during the preceding 90 days, treatment failure and decompensation of comorbidities were associated with pneumoniaunrelated hospital readmission within 30 days. Background and Aims: Echinococcosis or hydatid disease is caused by larvae of the tapeworm Echinococcus. Four species are recognised and the vast majority of infestation in humans are caused by E. granulosus. It causes cystic echinococcosis, which has a worlwide distribution most commonly in Asia. Humans are exposed less frequently to E. multilocularis, which causes alveolar echinococcosis. E. vogeli and E .oligarthrus are rare species and cause polycystic echinoccosis. 
